Table of contents


On 27 June 2016, orphan designation (EU/3/16/1672) was granted by the European Commission to Celgene Europe Limited, United Kingdom, for 3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione hydrochloride (also known as CC-122) for the treatment of diffuse large B-cell lymphoma.

The sponsorship was transferred to Celgene Europe B.V., The Netherlands, in January 2019.

Key facts

Active substance
3-(5-Amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione hydrochloride-
Disease / condition
Treatment of diffuse large B-cell lymphoma
Date of first decision
EU designation number

Sponsor's contact details

Celgene Europe B.V.
Winthontlaan 6 N
3526 KV Utrecht
The Netherlands
Tel. +31 30 284 4547

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating